Kidney Dosimetry in ¹⁷⁷Lu and ⁹⁰Y Peptide Receptor Radionuclide Therapy: Influence of Image Timing, Time-activity Integration Method, and Risk Factors

Overview

Journal Biomed Res Int

Publisher Wiley

Specialties Biomedical Engineering
Biotechnology
General Medicine

Date 2013 Jul 19

PMID 23865075

Citations 37

Authors

F Guerriero

M E Ferrari

F Botta

F Fioroni

E Grassi

A Versari

A Sarnelli

M Pacilio

E Amato

L Strigari

L Bodei

G Paganelli

M Iori

G Pedroli

M Cremonesi

Affiliations

Soon will be listed here.

Abstract

Kidney dosimetry in (177)Lu and (90)Y PRRT requires 3 to 6 whole-body/SPECT scans to extrapolate the peptide kinetics, and it is considered time and resource consuming. We investigated the most adequate timing for imaging and time-activity interpolating curve, as well as the performance of a simplified dosimetry, by means of just 1-2 scans. Finally the influence of risk factors and of the peptide (DOTATOC versus DOTATATE) is considered. 28 patients treated at first cycle with (177)Lu DOTATATE and 30 with (177)Lu DOTATOC underwent SPECT scans at 2 and 6 hours, 1, 2, and 3 days after the radiopharmaceutical injection. Dose was calculated with our simplified method, as well as the ones most used in the clinic, that is, trapezoids, monoexponential, and biexponential functions. The same was done skipping the 6 h and the 3 d points. We found that data should be collected until 100 h for (177)Lu therapy and 70 h for (90)Y therapy, otherwise the dose calculation is strongly influenced by the curve interpolating the data and should be carefully chosen. Risk factors (hypertension, diabetes) cause a rather statistically significant 20% increase in dose (t-test, P < 0.10), with DOTATATE affecting an increase of 25% compared to DOTATOC (t-test, P < 0.05).

Citing Articles

A review of 177Lu dosimetry workflows: how to reduce the imaging workloads?.

Vergnaud L, Dewaraja Y, Giraudet A, Badel J, Sarrut D EJNMMI Phys. 2024; 11(1):65.

PMID: 39023648 PMC: 11554969. DOI: 10.1186/s40658-024-00658-8.

Anatomy-based correction of kidney PVE on [Formula: see text] SPECT images.

Salvadori J, Allegrini O, Opsommer T, Carullo J, Sarrut D, Porot C EJNMMI Phys. 2024; 11(1):15.

PMID: 38316677 PMC: 11266336. DOI: 10.1186/s40658-024-00612-8.

Accuracy and uncertainty analysis of reduced time point imaging effect on time-integrated activity for Lu-DOTATATE PRRT in patients and clinically realistic simulations.

Peterson A, Mirando D, Dewaraja Y EJNMMI Res. 2023; 13(1):57.

PMID: 37306783 PMC: 10260735. DOI: 10.1186/s13550-023-01007-z.

Accuracy and uncertainty analysis of reduced time point imaging effect on time-integrated activity for 177Lu-DOTATATE PRRT in clinical patients and realistic simulations.

Peterson A, Mirando D, Dewaraja Y Res Sq. 2023; .

PMID: 37131738 PMC: 10153357. DOI: 10.21203/rs.3.rs-2829731/v1.

Voxel-Based Internal Dosimetry for Lu-Labeled Radiopharmaceutical Therapy Using Deep Residual Learning.

Kim K, Lee M, Suh M, Cheon G, Lee J Nucl Med Mol Imaging. 2023; 57(2):94-102.

PMID: 36998593 PMC: 10043146. DOI: 10.1007/s13139-022-00769-z.

References

Kletting P, Kull T, Reske S, Glatting G . Comparing time activity curves using the Akaike information criterion. Phys Med Biol. 2009; 54(21):N501-7. DOI: 10.1088/0031-9155/54/21/N01. View

Konijnenberg M . From imaging to dosimetry and biological effects. Q J Nucl Med Mol Imaging. 2011; 55(1):44-56. View

Bodei L, Cremonesi M, Ferrari M, Pacifici M, Grana C, Bartolomei M . Long-term evaluation of renal toxicity after peptide receptor radionuclide therapy with 90Y-DOTATOC and 177Lu-DOTATATE: the role of associated risk factors. Eur J Nucl Med Mol Imaging. 2008; 35(10):1847-56. DOI: 10.1007/s00259-008-0778-1. View

Sandstrom M, Garske U, Granberg D, Sundin A, Lundqvist H . Individualized dosimetry in patients undergoing therapy with (177)Lu-DOTA-D-Phe (1)-Tyr (3)-octreotate. Eur J Nucl Med Mol Imaging. 2009; 37(2):212-25. DOI: 10.1007/s00259-009-1216-8. View

Stabin M, Sparks R, Crowe E . OLINDA/EXM: the second-generation personal computer software for internal dose assessment in nuclear medicine. J Nucl Med. 2005; 46(6):1023-7. View

Garkavij M, Nickel M, Sjogreen-Gleisner K, Ljungberg M, Ohlsson T, Wingardh K . 177Lu-[DOTA0,Tyr3] octreotate therapy in patients with disseminated neuroendocrine tumors: Analysis of dosimetry with impact on future therapeutic strategy. Cancer. 2010; 116(4 Suppl):1084-92. DOI: 10.1002/cncr.24796. View

He B, Wahl R, Sgouros G, Du Y, Jacene H, Kasecamp W . Comparison of organ residence time estimation methods for radioimmunotherapy dosimetry and treatment planning--patient studies. Med Phys. 2009; 36(5):1595-601. PMC: 2851232. DOI: 10.1118/1.3100265. View

Baechler S, Hobbs R, Boubaker A, Buchegger F, He B, Frey E . Three-dimensional radiobiological dosimetry of kidneys for treatment planning in peptide receptor radionuclide therapy. Med Phys. 2012; 39(10):6118-28. PMC: 3465355. DOI: 10.1118/1.4752213. View

Filice A, Fraternali A, Frasoldati A, Asti M, Grassi E, Massi L . Radiolabeled somatostatin analogues therapy in advanced neuroendocrine tumors: a single centre experience. J Oncol. 2012; 2012:320198. PMC: 3425839. DOI: 10.1155/2012/320198. View

10.

Hindorf C, Chittenden S, Causer L, Lewington V, Macke H, Flux G . Dosimetry for (90)Y-DOTATOC therapies in patients with neuroendocrine tumors. Cancer Biother Radiopharm. 2007; 22(1):130-5. DOI: 10.1089/cbr.2007.306. View

11.

Kwekkeboom D, Kam B, Van Essen M, Teunissen J, van Eijck C, Valkema R . Somatostatin-receptor-based imaging and therapy of gastroenteropancreatic neuroendocrine tumors. Endocr Relat Cancer. 2009; 17(1):R53-73. DOI: 10.1677/ERC-09-0078. View

12.

Jackson A, Kutcher G, Yorke E . Probability of radiation-induced complications for normal tissues with parallel architecture subject to non-uniform irradiation. Med Phys. 1993; 20(3):613-25. DOI: 10.1118/1.597056. View

13.

Imhof A, Brunner P, Marincek N, Briel M, Schindler C, Rasch H . Response, survival, and long-term toxicity after therapy with the radiolabeled somatostatin analogue [90Y-DOTA]-TOC in metastasized neuroendocrine cancers. J Clin Oncol. 2011; 29(17):2416-23. DOI: 10.1200/JCO.2010.33.7873. View

14.

Wessels B, Konijnenberg M, Dale R, Breitz H, Cremonesi M, Meredith R . MIRD pamphlet No. 20: the effect of model assumptions on kidney dosimetry and response--implications for radionuclide therapy. J Nucl Med. 2008; 49(11):1884-99. DOI: 10.2967/jnumed.108.053173. View

15.

Baechler S, Hobbs R, Prideaux A, Wahl R, Sgouros G . Extension of the biological effective dose to the MIRD schema and possible implications in radionuclide therapy dosimetry. Med Phys. 2008; 35(3):1123-34. PMC: 2974633. DOI: 10.1118/1.2836421. View

16.

Larsson M, Bernhardt P, Svensson J, Wangberg B, Ahlman H, Forssell-Aronsson E . Estimation of absorbed dose to the kidneys in patients after treatment with 177Lu-octreotate: comparison between methods based on planar scintigraphy. EJNMMI Res. 2012; 2(1):49. PMC: 3506567. DOI: 10.1186/2191-219X-2-49. View

17.

Hobbs R, Sgouros G . Calculation of the biological effective dose for piecewise defined dose-rate fits. Med Phys. 2009; 36(3):904-7. PMC: 2736747. DOI: 10.1118/1.3070587. View

18.

Konijnenberg M . Is the renal dosimetry for [90Y-DOTA0,Tyr3]octreotide accurate enough to predict thresholds for individual patients?. Cancer Biother Radiopharm. 2003; 18(4):619-25. DOI: 10.1089/108497803322287718. View

19.

Sghedoni R, Grassi E, Fioroni F, Asti M, Piccagli V, Versari A . Personnel exposure in labelling and administration of (177)Lu-DOTA-D-Phe1-Tyr3-octreotide. Nucl Med Commun. 2011; 32(10):947-53. DOI: 10.1097/MNM.0b013e328349fd60. View

20.

Spiess A, Neumeyer N . An evaluation of R2 as an inadequate measure for nonlinear models in pharmacological and biochemical research: a Monte Carlo approach. BMC Pharmacol. 2010; 10:6. PMC: 2892436. DOI: 10.1186/1471-2210-10-6. View